BCL2 and primary cutaneous T-cell non-Hodgkin lymphoma: The idea of experimental designs is motivated by the work by Cyrenne et al. 41 and Kim et al. 42 that show that the combined knockdown of BCL2 and HDAC141 can be a promising treatment of CTCL.